Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022552 | 0.92 | ALDH1A1 (0.52) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL29932911 | 0.86 | MAOB (0.51) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL6273172 | 0.86 | MAOB (0.51) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL3925411 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL19384427 | 0.83 | MAOB (0.51) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL13097103 | 0.83 | CHRNB2 (0.60) | — | |
| SCHEMBL31173236 | 0.83 | MAOB (0.51) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL15060276 | 0.81 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL5835231 | 0.81 | FDPS (0.51) | KDM4EALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL6240987 | 0.81 | MAPK1 (0.54) | KDM4EALDH1A1LMNAKMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354931-B2 | Treating obstructive airway disorders using nontoxic drug | ROCHE PALO ALTO LLC (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1442032-B1 | HETEROCYCLIC RETINOID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20050049238-A1 | Heterocyclic retinoid compounds | KLAUS MICHAEL (DE) | 2005-03-03 | — | — | US | disclosed |
| US-6818652-B2 | THERAPEUTIC TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CANCER AND DERMATOLOGICAL SKIN DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1442032-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030158178-A1 | Heterocyclic retinoid compounds | SYNTEX (U.S.A.) LLC | 2003-08-21 | — | — | US | disclosed |
| WO-2003037882-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-0350846-B1 | Condensed heterocyclic compounds and their use in therapy | HOFFMANN LA ROCHE (CH) | 1995-10-11 | — | — | EP | disclosed |
| US-5420273-A | Skin disorders and antitumor agents | HOFFMAN-LA ROCHE INC. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5300522-A | Treating inflammatory, allergic, rheumatic, immunological disorders | HOFFMANN-LA ROCHE INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5164387-A | Antitumor agents, skin disorders, antiinflammatory agents | HOFFMANN-LAROCHE INC. (US) | 1992-11-17 | — | — | US | disclosed |
| US-5037825-A | Useful In The Treatment Of Neoplasms, Dermatoses And Aging Of The Skin | HOFFMANN-LA ROCHE INC. (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0350846-A2 | Condensed heterocyclic compounds and their use in therapy | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049238-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | KDM4E 3250/4885ALDH1A1 160/4885LMNA 1113/4885 |
| US-20030158178-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | KDM4E 3250/4885ALDH1A1 160/4885LMNA 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.